Eligibility, any sex, with Migraine Disorders. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
The Capsaicin-Induced Dermal Blood Flow (DBF)Primary· Baseline (pre-capsaicin) and on assessment day over approximately one hour, after at least a 4 month wash out from treatment in study NCT02163993
Change from pre-capsaicin DBF adjusting for vehicle at 30 minutes is reported. The capsaicin induced dermal blood flow (DBF) was measured by laser Doppler imaging (LDI).
Group
Value
95% CI
Placebo
606.1
± 615.6
120 mg Galcanezumab
599.5
± 514.7
300 mg Galcanezumab
689.2
± 552.3
Plasma Calcitonin Gene-Related Peptide (CGRP) LevelsPrimary· On assessment day over approximately one hour, after at least a 4 month wash out from treatment in study NCT02163993
The mean Plasma Calcitonin Gene-Related Peptide levels were reported.
Group
Value
95% CI
Placebo
1.748
± 1.322
120 mg Galcanezumab
1.082
± 0.261
300 mg Galcanezumab
1.370
± 0.318
Adverse events — posted to ClinicalTrials.gov
Time frame: Day 1 to Day 3.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This is a study of participants with a diagnosis of migraine who completed another clinical trial NCT02163993. The participants received either LY2951742 or placebo. This study NCT02766517 will evaluate how certain biomarkers may be related to the participant's response in study NCT02163993. The study will last about five days.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07237022 — The Role of TRP Channels in DPN
· recruiting
NCT06809569 — A Study to Evaluate Laser Speckle Contrast Imaging to Assess Changes in Chemical Agent-Induced Skin Blood Flow in Health
· Phase 1
· completed
NCT05958173 — Effects of 6-month of Treatment With TRPV1 and TRPA1 Agonists in Older Patients With OD
· NA
· unknown
NCT05983263 — Analgesic Efficacy of Capsaicin 8% Patch (QUTENZA®) in Coccygodygnia
· unknown
NCT07170176 — Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine
· NA
· recruiting
NCT07093138 — Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatmen
· Phase 4
· recruiting
NCT06426316 — The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology.
· NA
· recruiting
NCT06623188 — Treatment of Episodic Migraine With AURICular Neuromodulation
· NA
· recruiting
NCT06535880 — Trigeminal Brainstem Mapping 2: Higher Cortical Strucureas As Well As Subnuclei of the Spinal Trigeminal Nucleus
· NA
· recruiting
Other Eli Lilly and Company trials
Trials by the same sponsor.
NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
· Phase 2
· not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
· Phase 2
· not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants
· Phase 1
· completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants
· Phase 1
· completed
NCT07030127 — A Study of LY3985863 in Healthy Participants
· Phase 1
· completed
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 9 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02766517.